Tag: First-in-class DLL3 inhibitor

Home / First-in-class DLL3 inhibitor

Categories

Tarlatamab-dlle is granted accelerated approval by FDA for extensive stage small cell lung cancer

May 2024: Tarlatamab-dlle (Imdelltra, Amgen, Inc.) has received fast approval from the Food and Drug Administration for the treatment of extensive stage small cell lung cancer (ES-SCLC) in patients wh...
first-in-class-dll3-inhibitor

Scan the code